



SCAN TO VERIFY

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4260-BT48

BPC-157 / TB-500 (Wolverine) · Lot T-BPC-0025
Issued Oct 19, 2026 PT · v1
Verify: B6AC-4351-FBA1

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity

■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Brand	APEXX BIOLABS LLC	Product	BPC-157 / TB-500 (Wolverine)
Lot / Batch	T-BPC-0025	Label Claim	BPC-157 10 mg + TB-500 10 mg
Matrix	lyophilized powder	Sample Count	1
Cap Color	Black	Crimp Color	Silver / Aluminum
Contents Color	White	Seal Intact	Yes
Condition	sealed, intact	Received	Sep 24, 2026 PT
Sampling	client submitted		

Test Results

Test	Specification	Result	
Identity research screen	every declared component within ± 1 Da of its own theoretical mass	2 of 2 components confirmed	PASS
Purity research screen	each declared component at or above its own locked purity criterion	99.85%	PASS
Net Peptide Content research screen	each declared component within its own locked content criterion, at the declared ratio	21.06 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



Layer Results

1 Identity

LC-MS (ESI+)

2 of 2 components confirmed

 every declared component within ± 1 Da of its own theoretical mass

PASS

Component	Its criterion	Observed	Status
BPC-157	1419.556 Da · acceptance ± 1 Da · average	1419.7 Da	PASS Recorded component call: PASS Calculated comparison: within criterion Signed layer call: PASS
TB-500 (Thymosin B4)	4963.506 Da · acceptance ± 1 Da · average	4963.559 Da	PASS Recorded component call: PASS Calculated comparison: within criterion Signed layer call: PASS
Theoretical mass		1419.556 Da	Acceptance within ± 1 Da
Vial A		2 of 2 components confirmed	

Component	Theoretical	Observed	Mass error	Identity
BPC-157	1419.556 Da	1419.7 Da	+0.144 Da (101.4 ppm)	CONFIRMED
TB-500 (Thymosin B4)	4963.506 Da	4963.559 Da	+0.053 Da (10.7 ppm)	CONFIRMED

2 Purity

RP-HPLC 214nm (USP 621)

99.85%

each declared component at or above its own locked purity criterion

PASS

Component	Its criterion	Observed	Status
BPC-157	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.94%	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS
TB-500 (Thymosin B4)	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.76%	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS
Acceptance		Each component NLT 99.25 area %	Vial A 99.85% · PASS



SCAN TO VERIFY

3 Net Peptide Content

Quantitative HPLC vs reference std

21.06 mg

PASS

each declared component within its own locked content criterion, at the declared ratio

Component	Its criterion	Observed	Status
BPC-157	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for BPC-157/TB-500 (component ratio 1); acceptance $\pm 10\%$ per Axiom SPEC-CONTENT-001	10.49 mg	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS
TB-500 (Thymosin B4)	1 part · 9–11 mg · Declared blend recipe on the controlled Axiom catalog record for BPC-157/TB-500 (component ratio 1); acceptance $\pm 10\%$ per Axiom SPEC-CONTENT-001	10.57 mg	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS

Observed ratio **BPC-157 1.00 : TB-500 (Thymosin B4) 1.01** against declared **BPC-157 1.00 : TB-500 (Thymosin B4) 1.00** · source Declared blend recipe on the controlled Axiom catalog record for BPC-157/TB-500 (component ratio 1); acceptance $\pm 10\%$ per Axiom SPEC-CONTENT-001

Target	20 mg ($\pm 10\%$)	Confirmed container volume	Unknown
Content concentration	Unknown		

4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected

Rapid PCR screen

PASS

Result	Target DNA not detected	Acceptance	Rapid PCR screen
--------	-------------------------	------------	------------------

8 Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.



CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER
(L8)



Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4260-BT48

BPC-157 / TB-500 (Wolverine) · Lot T-BPC-0025

Issued Oct 19, 2026 PT · v1
Verify: B6AC-4351-FBA1

Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:9c65ab182637c029bf70074a...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:18fc4ed14b1560ee9f06c849...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:90e97956a48b5b75b787ce32...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-4260-BT48>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: a00e46461f6a3f7e650c159e307c00292d2d33b29b020be45411ebfe1b7e2ac0...

Seal: ed25519:c9feadd23fe85e1cbaf95751f9001aaf55df9e38...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.